Pfizer Now Advancing GL-2045
GL-2045, our first stradomerTM advancing in development, has shown promising results in a broad range of preclinical tests and is now being developed by Pfizer as a potential treatment for a variety of autoimmune diseases.
Gliknik and Pfizer entered into a licensing agreement for GL-2045 development in September 2013. Today, the compound is in large-scale manufacturing and we expect it to rapidly progress into clinical development.
Featured Pipeline Program
By harnessing the power of the immune system, GL-0817 is designed as a new approach to cancer. It has a number of built-in features not available in any competitive cancer therapeutic vaccine. To date, GL-0817 has been studied in people living with head and neck cancers and with multiple myeloma.
From the earliest stages of research, Gliknik researchers attempt to ensure that our areas of scientific focus are on unmet medical needs where we can create a competitive advantage and develop medicines that will make a difference in the lives of patients.
At Gliknik, our mission is to discover and develop truly innovative biologics for people living with cancer and immune disorders. Headquartered in downtown Baltimore’s medical research community, Gliknik’s expertise is in modulation of the immune system to fight disease.
Our perseverance and determination to make a difference in the lives of individuals with cancer and autoimmune disease is evidenced by the assembly of a talented team of scientists, augmented by our Board members, scientific advisors and a network of worldwide scientific and medical thought leaders.